Orphazyme aims for Parkinson's breakthrough – early candidates also on the table
Biotech firm Orphazyme is developing multiple new drug candidates for Parkinson's disease stemming from the company's dealings with the drug Arimoclomol. The goal is to create a new standard treatment, which can slow or halt the disease entirely.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
As the Copenhagen-based biotech firm Orphazyme awaits the landmark approval of the firm's first drug Arimoclomol, the firm's researchers are already betting on a new pharmaceutical venture, which might become the company's future hope.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
